Pilot study of Resveratrol in patients with Glaucoma
An open label clinical pilot study of the effect of resveratrol in patients with Glaucoma
Centre for Eye Research Australia
30 participants
Jul 1, 2012
Interventional
Conditions
Summary
The primary aims of this study are to determine whether the electroretinogram (ERG), particularly the Phototopic negative response (PhNR) can be improved in patients with glaucoma who take oral supplementation with Resveratrol (RSV) of different doses. Participants undertake full-field ERG testing and their recordings of responses are examined to determine whether there is a difference in ERG parameters between glaucoma patients taking different doses of RSV and after a wash-out period after stopping RSV.
Eligibility
Inclusion Criteria1
- Patients with ocular hypertension, mild to moderate glaucoma
Exclusion Criteria4
- Advanced glaucoma
- Pregnancy
- Severe renal or hepatic impairment
- Documented allergy to Resveratrol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dose escalation study where patients with glaucoma are given 1 gram Resveratrol (oral capsule) daily for 2 weeks followed by 5 grams of Resveratrol (oral capsule) daily for 2 weeks.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000258853